- PDS Biotechnology ( NASDAQ: PDSB ) is up 3% in premarket trading on results on the company's triple combination therapy for human papillomavirus (HPV)-positive cancers.
- The triple combination includes the company's PDS0101, the tumor-targeting IL-12 fusion protein M9241, and bintrafusp alfa.
- All participants had failed on chemo and 90% had failed on radiation treatment.
- Results showed that out of 29 patients who failed on checkpoint inhibitors, the median overall survival ( OS ) was 21. months. The historical median OS in patients in this group is three to four months.
- The objective response rate (ORR) in checkpoint inhibitor ("CPI") naïve patients with the triple combination was 88%. The ORR is reported to be less than 25% with CPIs in HPV-associated cancers.
- Read why BioSci Capital Partners views PDS Biotechnology ( PDSB ) as a buy.
For further details see:
PDS Biotechnology up 3% after reporting data on triple combination for HPV cancers